Efficacy and Safety of PEMbrolizumab PD-L1-positive (>50% of Tumor Cells), Advanced NSCL Cancer(PEMBREIZH)
NCT05321212
·
clinicaltrials.gov ↗
COMPLETED
Status
108
Enrollment
OTHER
Sponsor class
Conditions
Carcinoma, Non-Small-Cell Lung
Immunotherapy
Sponsor
University Hospital, Brest